China's former SFDA chief executed

25 July 2007

The former Director of China's State Food and Drug Administration, Zheng Xiaoyu, was executed on July 10, after the country's Supreme Court endorsed the sentence which was passed for taking nearly 6.5 million renminbi ($853,000) in bribes and dereliction of duty (Marketletters June 4 and 18). Mr Zheng had pleaded guilty to both charges.

Although the disgraced former drug regulator offered information after his conviction, in an attempt to have his sentence reduced, the Supreme Court stated that no new evidence had been provided to prosecutors.

A spokeswoman for the SFDA responded to the news of Me Zheng's death and the announcement that one of his deputies, Cao Wenzhuang (who headed the agency's drug registration department), had received a suspended death sentence (Marketletter July 16). Yan Jiangying said: "we should seriously reflect and learn lessons from these cases."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight